Sheng Hou

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

Shi Hu, Shuaiyi Liang, Huaizu Guo et al. · Journal of Biological Chemistry · 2013 · 156 citations · Full text

Medicine, Immunology, Pharmacology +17

Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab

Shuaiyi Liang, Jianxin Dai, Sheng Hou et al. · Journal of Biological Chemistry · 2013 · 110 citations · Full text

Life Sciences, Immunology, Immunopathology +14

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin

Huafeng Wei, Likun Zhao, Wei Li et al. · PLoS ONE · 2013 · 106 citations · Full text

Life Sciences, Immunology, Oncology +17

Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses

Boning Liu, Huaizu Guo, Jin Xu et al. · mAbs · 2017 · 95 citations · Full text

Life Sciences, Immunology, Oncology +17

Targeted Delivery of Tumor Antigens to Activated Dendritic Cells via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Huafeng Wei, Suhui Wang, Dapeng Zhang et al. · Clinical Cancer Research · 2009 · 83 citations

Life Sciences, Immunology, Oncology +17